PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsmyeloid leukemia acute
MeSH D015470 - myeloid leukemia acute
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D007951:Myeloid leukemia
25 Companies
7 Drugs
$
Success rate
D015470: 
Myeloid leukemia acute
50 Companies
17 Drugs
$
Success rate
D004915:Erythroblastic leukemia acute
0 Companies
0 Drugs
Success rate
D007946:Mast-cell leukemia
0 Companies
0 Drugs
Success rate
D007947:Megakaryoblastic leukemia acute
0 Companies
0 Drugs
Success rate
D007948:Monocytic leukemia acute
0 Companies
0 Drugs
Success rate
D015471:Basophilic leukemia acute
1 Company
1 Drug
$
Success rate
D015472:Eosinophilic leukemia acute
1 Company
1 Drug
$
Success rate
D015473:Promyelocytic leukemia acute
29 Companies
7 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaDaunorubicin Daunorubicin  1998-06-23   
Doxorubicin Doxorubicin  1995-07-28   
Etoposide Etoposide  1994-02-10   
Idarubicin Idarubicin  2002-05-01   
Doxorubicin Myocet (previously Myocet)  2000-07-13   
Cyclophosphamide Neosar  1993-04-29   
Etoposide Toposar  1995-02-27   
IngenusCyclophosphamide Cyclophosphamide 2036-02-15 2020-07-30   
MylanAzacitidine Azacitidine Mylan  2020-03-27   
Doxorubicin Doxorubicin  2011-10-28   
Etoposide Etoposide  2001-09-19   
Rising PharmaceuticalsIdarubicin Idarubicin  2012-10-11   
Mitoxantrone Mitoxantrone  2012-12-11   
CiplaCyclophosphamide Cyclophosphamide  2019-01-18   
SandozIdarubicin Idarubicin  2011-03-29   
Cyclophosphamide Cyclophosphamide  2023-09-12   
NovartisMidostaurin Rydapt 2022-10-29 2017-04-28   
SanofiDaunorubicin Cerubidine  1982-01-01   
WyethDaunorubicin Cerubidine  1982-01-01   
Gemtuzumab ozogamicin Mylotarg  2017-09-01   
PfizerDoxorubicin Adriamycin  1991-01-30   
Glasdegib Daurismo 2028-06-29 2018-11-21   
Doxorubicin Doxorubicin  1982-01-01   
Idarubicin Idamycin  1990-09-27   
Gemtuzumab ozogamicin Mylotarg  2018-04-19   
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
68%
196/287
Phase 2
43%
110/257
Phase 3
33%
49/150
Approved: 25Overall Success rate: 10%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Cyclophosphamide,
Doxorubicin,
Doxorubicin hydrochloride,
Etoposide,
Idarubicin
Novartis
Midostaurin,
Tbo-filgrastim,
Magrolimab,
Sabatolimab,
Spartalizumab,
Lenograstim,
Dovitinib,
Mitoguazone,
Vatalanib,
Aprinocarsen,
Regramostim,
Gemtuzumab,
Molgramostim,
SIREMADLIN,
Sodium lactate,
Microcrystalline cellulose,
Anthracycline,
Vob560,
Magnolia,
Mik665,
Magma
Sanofi
Daunorubicin,
Daunorubicin hydrochloride,
Mycophenolate sodium,
Tbo-filgrastim,
Cilmostim,
Lenograstim,
Regramostim,
Molgramostim,
Sodium chloride,
Sodium lactate,
Microcrystalline cellulose,
Sar445419,
Sar103168
Pfizer
Glasdegib,
Gemtuzumab ozogamicin,
Doxorubicin,
Doxorubicin hydrochloride,
Idarubicin,
Guadecitabine,
Lampalizumab,
Etrolizumab,
Lenograstim,
Regramostim,
Gemtuzumab,
FILANESIB,
FOSMANOGEPIX,
Magnolia,
Magma
Dr Reddys Laboratories
Doxorubicin,
Doxorubicin hydrochloride
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use